Low immunogenicity of tocilizumab in patients with rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 76, Issue 6, 2017, Pages 1078-1085

  Burmester, Gerd R ^a   Choy, Ernest ^b   Kivitz, Alan ^c   Ogata, Atsushi ^d,e   Bao, Min ^f   Nomura, Akira ^g   Lacey, Stuart ^h   Pei, Jinglan ^f   Reiss, William ^f   Pethoe Schramm, Attila ⁱ   Mallalieu, Navita L ^j   Wallace, Thomas ^f   Michalska, Margaret ^f   Birnboeck, Herbert ⁱ   Stubenrauch, Kay ^k   Genovese, Mark C ^l  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c Altoona Center for Clinical Research   (United States)

^d OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e Rheumatology and Connective Tissue Diseases   (Japan)

^f GENENTECH INC   (United States)

^g CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^h ROCHE PRODUCTS LTD   (United Kingdom)

ⁱ F HOFFMANN LA ROCHE LTD   (Switzerland)

^j Roche Innovation Center   (United States)

^k ROCHE INNOVATION CENTER MUNICH   (Germany)

^l STANFORD UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

Autoantibodies; DMARDs (biologic); Rheumatoid Arthritis

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; DRUG ANTIBODY; IMMUNOGLOBULIN E ANTIBODY; TOCILIZUMAB; ANTIBODY; MONOCLONAL ANTIBODY;

ANAPHYLAXIS; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ARTICLE; COMBINATION CHEMOTHERAPY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HYPERSENSITIVITY; IMMUNOGENICITY; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TREATMENT INTERRUPTION; TREATMENT RESPONSE; ARTHRITIS, RHEUMATOID; BLOOD; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; DRUG HYPERSENSITIVITY; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; SUBCUTANEOUS DRUG ADMINISTRATION;

ADMINISTRATION, INTRAVENOUS; ANAPHYLAXIS; ANTIBODIES; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG HYPERSENSITIVITY; DRUG THERAPY, COMBINATION; HUMANS; INJECTIONS, SUBCUTANEOUS;

EID: 85007524784     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-210297     Document Type: Article

References (43)

1. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
2. Singh SK. Impact of product-related factors on immunogenicity of biotherapeutics. J Pharm Sci 2011;100:354-87.
3. Jani M, Barton A, Warren RB, et al. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxford) 2014;53:213-22.
4. Keiserman M, Codreanu C, Handa R, et al. The effect of antidrug antibodies on the sustainable efficacy of biologic therapies in rheumatoid arthritis: practical consequences. Expert Rev Clin Immunol 2014;10:1049-57.
5. Maneiro JR, Salgado E, Gomez-Reino JJ. Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: systematic review and meta-Analysis. JAMA Intern Med 2013;173:1416-28.
6. Garcês S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: A systematic review of the literature with a meta-Analysis. Ann Rheum Dis 2013;72:1947-55.
7. Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-Term follow-up. JAMA 2011;305:1460-8.
8. Vincent FB, Morand EF, Murphy K, et al. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: A real issue, a clinical perspective. Ann Rheum Dis 2013;72:165-78.
9. Braun J, Kudrin A. Progress in biosimilar monoclonal antibody development: The infliximab biosimilar CT-P13 in the treatment of rheumatic diseases. Immunotherapy 2015;7:73-87.
10. van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2013;9:164-72.
11. Maggi E, Vultaggio A, Matucci A. Acute infusion reactions induced by monoclonal antibody therapy. Expert Rev Clin Immunol 2011;7:55-63.
12. Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2005;106:2627-32.
13. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987-97.
14. Kremer JM, Blanco R, Brzosko M, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011;63:609-21.
15. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Ann Rheum Dis 2010;69:88-96.
16. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-Tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23.
17. Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58:2968-80.
18. De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367:2385-95.
19. Brunner HI, Ruperto N, Zuber Z, et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis 2015;74:1110-17.
20. Burmester GR, Rubbert-Roth A, Cantagrel A, et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis 2014;73:69-74.
21. Burmester GR, Rubbert-Roth A, Cantagrel A, et al. Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA). Ann Rheum Dis 2016;75:68-74.
22. Kivitz A, Olech E, Borofsky M, et al. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2014;66:1653-61.
23. Kivitz A, Olech E, Borofsky MA, et al. The efficacy and safety of tocilizumab subcutaneous Q2W and following escalation from Q2W to QW therapy in combination with traditional DMARDs in patients with moderate to severe rheumatoid arthritis at 96 weeks [abstract]. Arthritis Rheumatol 2014;66:S1076-7.
24. Kivitz A, Michalska M, Devenport J, et al. A multicenter, open-label, long-Term extension study of SUMMACTA and BREVACTA to evaluate safety and efficacy of tocilizumab SC in patients with moderate to severe RA [abstract]. Ann Rheum Dis 2015;74(Suppl 2):720.
25. Ogata A, Tanimura K, Sugimoto T, et al. Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2014;66:344-54.
26. Ogata A, Amano K, Dobashi H, et al. Longterm safety and efficacy of subcutaneous tocilizumab monotherapy: results from the 2-year open-label extension of the MUSASHI study. J Rheumatol 2015;42:799-809.
27. Burmester GR, Rigby WF, van Vollenhoven RF, et al. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann Rheum Dis 2016;75:1081-91.
28. Actemra® prescribing information. Genentech, Inc., a Member of the Roche Group, South San Francisco, CA, USA, 2010.
29. Stubenrauch K, Wessels U, Birnboeck H, et al. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing. Clin Ther 2010;32:1597-609.
30. Sampson HA, Muñoz-Furlong A, Campbell RL, et al. Second Symposium on the definition and management of anaphylaxis: summary report-Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006;117:391-7.
31. Burmester GR, Bao M, Reiss W, et al. Immunogenicity, safety and efficacy of subcutaneous tocilizumab in patients who missed doses [abstract]. Ann Rheum Dis 2015;74(Suppl 2):478.
32. Rodríguez-Muguruza S, Quirant B, Teniente A, et al. Tocilizumab serum levels and antidrug antibodies and its relationship with disease activity in rheumatic diseases [abstract]. Ann Rheum Dis 2015;74:731.
33. Sigaux J, Hamze M, Daien C, et al. Immunogenicity of tocilizumab in patients with rheumatoid arthritis. Joint Bone Spine 2016; Published Online First: 28 Jun 2016. http://dx.doi.org/10.1016/j.jbspin.2016.04.013
34. Benucci M, Meacci F, Grossi V, et al. Correlations between immunogenicity, drug levels, and disease activity in an Italian cohort of rheumatoid arthritis patients treated with tocilizumab. Biologics 2016;10:538.
35. Weinblatt ME, Kremer J, Cush J, et al. Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: Twenty-four-week results of an open-label, clinical practice study. Arthritis Care Res (Hoboken) 2013;65:362-71.
36. Dougados M, Kissel K, Sheeran T, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis 2013;72:43-50.
37. Bykerk VP, Östör AJ, Alvaro-Gracia J, et al. Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: An open-label study close to clinical practice. Clin Rheumatol 2015;34:563-71.
38. Choy E, Caporali R, Xavier R, et al. Subcutaneous tocilizumab as monotherapy or in combination with a csDMARD in patients with rheumatoid arthritis-interim analysis of a large phase IV international umbrella study, "TOZURA" [abstract]. Ann of the Rheum Dis 2016;75(Suppl 2)509-10.
39. Krintel SB, Grunert VP, Hetland ML, et al. The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure. Rheumatology (Oxford) 2013;52:1245-53.
40. Burmester GR, Kivitz AJ, Kupper H, et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: The randomised CONCERTO trial. Ann Rheum Dis 2015;74:1037-44.
41. Nechansky A. HAHA-nothing to laugh about. Measuring the immunogenicity (human anti-human antibody response) induced by humanized monoclonal antibodies applying ELISA and SPR technology. J Pharm Biomed Anal 2010;51:252-4.
42. Spinelli FR, Valesini G. Immunogenicity of anti-Tumour necrosis factor drugs in rheumatic diseases. Clin Exp Rheumatol 2013;31:954-63.
43. Jani M, Chinoy H, Warren RB, et al. Clinical utility of random anti-Tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-Term treatment response in rheumatoid arthritis. Clin Exp Rheumatol 2015;67:2011-19.